140 related articles for article (PubMed ID: 27001186)
1. A phase II clinical trial of fludarabine and cyclophosphamide followed by thalidomide for angioimmunoblastic T-cell lymphoma. An NCRI clinical trial. CRUK number C17050/A5320.
Townsend W; Johnson RJ; Pottinger BT; Counsell N; Smith P; Chadwick H; Evans K; Wickham C; Rudin CE;
Leuk Lymphoma; 2016 Sep; 57(9):2232-4. PubMed ID: 27001186
[No Abstract] [Full Text] [Related]
2. Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia-type T-cell lymphoma with fludarabine.
Tsatalas C; Margaritis D; Kaloutsi V; Martinis G; Kotsianidis I; Bourikas G
Acta Haematol; 2001; 105(2):106-8. PubMed ID: 11408715
[No Abstract] [Full Text] [Related]
3. Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pre-treated patients with chronic lymphocytic leukemia.
Laurenti L; Piccioni P; Tarnani M; De Padua L; Garzia M; Efremov DG; Piccirillo N; Chiusolo P; Sica S; Leone G
Leuk Res; 2007 Feb; 31(2):253-6. PubMed ID: 16815546
[TBL] [Abstract][Full Text] [Related]
4. Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA.
Delfau-Larue MH; de Leval L; Joly B; Plonquet A; Challine D; Parrens M; Delmer A; Salles G; Morschhauser F; Delarue R; Brice P; Bouabdallah R; Casasnovas O; Tilly H; Gaulard P; Haioun C
Haematologica; 2012 Oct; 97(10):1594-602. PubMed ID: 22371178
[TBL] [Abstract][Full Text] [Related]
5. Single-agent lenalidomide is effective in the treatment of a heavily pretreated and refractory angioimmunoblastic T-cell lymphoma patient.
Broccoli A; Pellegrini C; Celli M; Argnani L; Agostinelli C; Pileri S; Zinzani PL
Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):e119-22. PubMed ID: 24629851
[No Abstract] [Full Text] [Related]
6. Successful treatment with fludarabine in two cases of angioimmunoblastic lymphadenopathy with dysproteinemia.
Hast R; Jacobsson B; Petrescu A; Hjalmar V
Leuk Lymphoma; 1999 Aug; 34(5-6):597-601. PubMed ID: 10492085
[TBL] [Abstract][Full Text] [Related]
7. Treatment of angioimmunoblastic lymphadenopathy with dysproteinemia-type T-cell lymphoma with fludarabine.
Tsatalas C; Margaritis D; Pantelidou D; Spanudakis E; Kaloutsi V; Bourikas G
Acta Haematol; 2003; 109(2):110. PubMed ID: 12624498
[No Abstract] [Full Text] [Related]
8. Therapy refractory angioimmunoblastic T-cell lymphoma in complete remission with lenalidomide.
Beckers MM; Huls G
Eur J Haematol; 2013 Feb; 90(2):162-3. PubMed ID: 23227803
[TBL] [Abstract][Full Text] [Related]
9. Uncommon late relapse of angioimmunoblastic T-cell lymphoma after 16-year remission period.
Páyer E; Miltényi Z; Simon Z; Szabados L; Hegyi K; Méhes G; Illés A
Pathol Oncol Res; 2012 Jul; 18(3):737-41. PubMed ID: 22127590
[No Abstract] [Full Text] [Related]
10. Unusual relapse of an angioimmunoblastic T cell lymphoma 11 years after initial manifestation.
Lohneis P; Jakob C; Hummel M; Jöhrens K; Anagnostopoulos I
Ann Hematol; 2015 Feb; 94(2):347-9. PubMed ID: 24923452
[No Abstract] [Full Text] [Related]
11. Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pretreated patients with chronic lymphocytic leukemia.
Giannopoulos K; Dmoszyńska A; Roliński J
Leuk Res; 2007 Mar; 31(3):411-2. PubMed ID: 16978694
[No Abstract] [Full Text] [Related]
12. Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia with fludarabine.
Ong ST; Koeppen H; Larson RA; Olopade OI
Blood; 1996 Sep; 88(6):2354-5. PubMed ID: 8822958
[No Abstract] [Full Text] [Related]
13. [Clinical features and prognostic factors of angioimmunoblastic T cell lymphoma].
Qin Y; Shi YK; He XH; Yang JL; Zhang CG; Zhou SY; Liu XF; Liu P; Yang S; Zhou LQ; Han XH; Yao JR
Zhonghua Zhong Liu Za Zhi; 2010 Jun; 32(6):448-51. PubMed ID: 20819488
[TBL] [Abstract][Full Text] [Related]
14. Elevated absolute monocyte count predicts unfavorable outcomes in patients with angioimmunoblastic T-cell lymphoma.
Yang YQ; Liang JH; Wu JZ; Wang L; Qu XY; Cao L; Zhao XL; Huang DP; Fan L; Li JY; Xu W
Leuk Res; 2016 Mar; 42():88-92. PubMed ID: 26764222
[TBL] [Abstract][Full Text] [Related]
15. Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM/IMVP-16 regimen. A multicenter study. Kiel Lymphoma Study Group.
Siegert W; Agthe A; Griesser H; Schwerdtfeger R; Brittinger G; Engelhard M; Kuse R; Tiemann M; Lennert K; Huhn D
Ann Intern Med; 1992 Sep; 117(5):364-70. PubMed ID: 1380221
[TBL] [Abstract][Full Text] [Related]
16. Neuropathy associated with angioimmunoblastic lymphadenopathy-like T-cell lymphoma.
Sonobe M; Yasuda H; Okabe H; Terada M; Maeda K; Kawabata T; Kikkawa R
Intern Med; 1998 Jul; 37(7):631-4. PubMed ID: 9711895
[TBL] [Abstract][Full Text] [Related]
17. Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation.
Schetelig J; Fetscher S; Reichle A; Berdel WE; Beguin Y; Brunet S; Caballero D; Majolino I; Hagberg H; Johnsen HE; Kimby E; Montserrat E; Stewart D; Copplestone A; Rösler W; Pavel J; Kingreen D; Siegert W
Haematologica; 2003 Nov; 88(11):1272-8. PubMed ID: 14607756
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen.
Klasa RJ; Meyer RM; Shustik C; Sawka CA; Smith A; Guévin R; Maksymiuk A; Rubinger M; Samosh M; Laplante S; Grenier JF
J Clin Oncol; 2002 Dec; 20(24):4649-54. PubMed ID: 12488409
[TBL] [Abstract][Full Text] [Related]
19. A four-year spontaneous remission of angioimmunoblastic T-cell lymphoma.
Cornish N; Maybury B; Otton S
Br J Haematol; 2018 Jan; 180(2):176. PubMed ID: 29048103
[No Abstract] [Full Text] [Related]
20. Ultra-high level of serum soluble interleukin-2 receptor at diagnosis predicts poor outcome for angioimmunoblastic T-cell lymphoma.
Shiratori S; Kosugi-Kanaya M; Shigematsu A; Kobayashi H; Yamamoto S; Kobayashi N; Iwasaki H; Mori A; Kunieda Y; Yutaka T; Kurosawa M; Kakinoki Y; Endo T; Kondo T; Hashino S; Teshima T;
Leuk Lymphoma; 2015; 56(9):2592-7. PubMed ID: 25563559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
